{
    "id": 11803,
    "fullName": "TRIM33 - RET",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "TRIM33-RET (also referred to as PTC7 and RFG7-RET) results from the fusion of TRIM33 and RET (PMID: 23533264). TRIM33-RET has been identified in lung adenocarcinoma (PMID: 23533264) and papillary thyroid carcinoma (PMID: 10741739), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 5430,
                    "pubMedId": 10741739,
                    "title": "Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10741739"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3648,
                    "pubMedId": 23533264,
                    "title": "Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23533264"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 51592,
        "geneSymbol": "TRIM33",
        "terms": [
            "TRIM33",
            "ECTO",
            "PTC7",
            "RFG7",
            "TF1G",
            "TIF1G",
            "TIF1GAMMA",
            "TIFGAMMA"
        ]
    },
    "variant": "TRIM33 - RET",
    "createDate": "09/15/2015",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 9725,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Cometriq (cabozantinib) demonstrated activity in patients with RET-rearranged lung adenocarcinoma, including a partial response in a patient harboring TRIM33-RET (PMID: 27825636; NCT01639508).",
            "molecularProfile": {
                "id": 11900,
                "profileName": "TRIM33 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7513,
                    "pubMedId": 27825636,
                    "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27825636"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11900,
            "profileName": "TRIM33 - RET",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}